MetaCap

Cognition Therapeutics (CGTX) vs Eloxx Pharmaceuticals (ELOX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cognition Therapeutics is the larger company by market cap ($55.4 million vs $43.7 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CGTX-49.37%ELOX-2.91%
+98%+21%-56%
Jun 9, 20261 yearNov 20, 2026
CGTX-51.88%ELOX-20.93%
+61%+2%-57%
Jun 8, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CGTX versus ELOX key metrics
MetricCGTXELOX
Share price$0.5822$10.69
Market cap$55.37M$43.69M
1-day change-3.06%-1.75%
YTD return-56.87%—
1-year return-58.12%—
5-year return-93.47%—
P/E ratio (TTM)—5.63
EPS (TTM)$-0.16$1.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-23.49M$-6.00M
52-week high$1.81$23.40
52-week low$0.55$8.20
Distance from 52-week high-67.83%-54.32%
Analyst consensusstrong_buynone
Avg. price target upside+471.97%+257.81%
Average volume464.94K28.48K
Shares outstanding95.10M4.09M
Employees1410
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cognition Therapeutics

CGTX stock →

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees

About Eloxx Pharmaceuticals

ELOX stock →

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees

CGTX vs ELOX FAQ

Which is bigger, Cognition Therapeutics or Eloxx Pharmaceuticals?

Cognition Therapeutics (CGTX) is larger, with a market capitalization of $55.37M compared with $43.69M for Eloxx Pharmaceuticals (ELOX).

Are Cognition Therapeutics and Eloxx Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons